The Impact of COVID-19
on Clinical Research

 

CLICK TO LEARN MORE

What is the

Heart Failure Collaboratory (HFC)?

Efficiency of clinical trials and evidence generation in heart failure and foster development of therapies by creating a collaborative environment in which FDA, government agencies including NIH and CMS, and the heart failure community can interact to optimize innovation and advancement of new therapeutic products. HFC has established five working groups to tackle individual issues in clinical trials and fostering the development of effective heart failure therapies.


The Heart Failure Collaboratory is a public-private partnership with the FDA and the consortium to help foster the development of new products for heart failure.

Recent Publications

Access our latest publications, downloads and meeting notes.
Approaches to the Treatment of Heart Failure in an Era of Multiple Therapies
The treatment of heart failure with reduced ejection fraction (HFrEF) has changed considerably over time, particularly with the sequential development of therapies aimed at antagonism of maladaptive biologic pathways.
Putting the “Optimal” in Optimal Medical Therapy
Despite rigorous data supporting the benefits of optimal medical therapy (OMT) as recommended by the guidelines for patients with heart failure (HF) with reduced ejection fraction, the implementation and maximization of these therapies in the “real world” continues to be challenging.
Changing U.S. Heart Failure Research Culture: Part 2—Recognizing Frontline Investigators and Coordinators
As we continue to obstacles to the heart failure therapeutic development process through the work of the Heart Failure Collaboratory (HFC), the challenge of site-based research remains.